178 related articles for article (PubMed ID: 16052675)
1. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.
Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS
World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
Wang FQ; Shang BY; Zhen YS
Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
Liu XY; Zhen YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody].
Dai Y; Liu XJ; Zhen YS
Yao Xue Xue Bao; 2006 Jan; 41(1):41-6. PubMed ID: 16683526
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase.
Fengqiang W; Boyang S; Yongsu Z
Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678
[TBL] [Abstract][Full Text] [Related]
8. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effects of the immunoconjugate composed of anti-type IV collagenase antibody Fab' fragment and lidamycin on tumor invasion and metastasis].
Feng Y; He HW; Li BW; Zhang ZX; Chen X; Li XF
Yao Xue Xue Bao; 2011 Dec; 46(12):1462-5. PubMed ID: 22375419
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.
Huang YH; Shang BY; Zhen YS
World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019
[TBL] [Abstract][Full Text] [Related]
11. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Shang BY; Shang Y; Zhen YS; Chen SZ
Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
[TBL] [Abstract][Full Text] [Related]
12. Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor.
Zhen HY; Huang YH; Zhen YS
Yao Xue Xue Bao; 2005 Dec; 40(12):1110-5. PubMed ID: 16496675
[TBL] [Abstract][Full Text] [Related]
13. [Immunoscintigraphy of anti-type IV collagenase monoclonal antibody in nude mice bearing human lung cancer xenograft].
Dai Y; Jia B; Wang F; Du J; Shang BY; Zhen YS
Ai Zheng; 2003 Dec; 22(12):1243-8. PubMed ID: 14693044
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitory effect of lidamycin on growth of colon carcinoma 26 and hepatic metastasis in mice].
Liu XJ; Dai Y; Shang Y; Li Y; Zhen YS
Ai Zheng; 2005 Jun; 24(6):641-5. PubMed ID: 15946470
[TBL] [Abstract][Full Text] [Related]
16. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
18. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
[TBL] [Abstract][Full Text] [Related]
19. Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway.
Liu X; Bian C; Ren K; Jin H; Li B; Shao RG
Oncol Rep; 2007 Mar; 17(3):597-603. PubMed ID: 17273739
[TBL] [Abstract][Full Text] [Related]
20. Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells.
Wang Z; He Q; Liang Y; Wang D; Li YY; Li D
Biochem Pharmacol; 2003 Jun; 65(11):1767-75. PubMed ID: 12781328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]